Portal Therapeutics, a GondolaBio affiliate, is developing PORT-77 for erythropoietic protoporphyria and X-linked protoporphyria, rare conditions associated with painful light sensitivity and liver complications. The investigational oral medicine inhibits ABCG2 to reduce the movement of protoporphyrin IX into plasma and the biliary tract. It received FDA Orphan Drug and Fast Track designations in October 2025. [1]
In June 2026, GondolaBio announced that its Phase 2a GATEWAY study met its plasma-protoporphyrin endpoint, reporting mean reductions of 79% in the high-dose group and 63% in the low-dose group. The results support further clinical development of PORT-77. [2]